Viewing Study NCT00610961


Ignite Creation Date: 2025-12-24 @ 1:07 PM
Ignite Modification Date: 2025-12-29 @ 11:03 AM
Study NCT ID: NCT00610961
Status: COMPLETED
Last Update Posted: 2011-09-27
First Post: 2008-01-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Induction Related BK Viremia in Renal Transplant Patients
Sponsor: University of Florida
Organization:

Study Overview

Official Title: The Induction Agent Effect on BK Viremia in Renal and Pancreas Transplant Patients
Status: COMPLETED
Status Verified Date: 2011-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BK
Brief Summary: The increase immunosuppression in our transplant population has led to an unacceptable rate of patients at risk for BK virus nephropathy. Reducing induction immunosuppression by switching from Thymoglobulin to Simulect will reduce the incidence of serum positivity for BK by PCR.
Detailed Description: Our standard of care has been changed from Thymoglobulin to Simulect and now patients were enrolled in this observational trial to gather data on their outcomes related to BK viremia and rejection rates. Two groups of patients were compared.

Retrospective (historical or control) group of subjects: patients who had received a kidney transplant and were inducted with Thymoglobulin prior to study initiation.

Prospective group of subjects: patients who is scheduled to receive kidney transplant and will be inducted with Simulect (Basiliximab).

Inductions in both groups was/is Standard of Care at a time of treatment.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: